pLX304-EZH1-dPSET
(Plasmid
#203586)
-
PurposeExpresses V5-tagged mutant version of EZH1 with deletion of aa 744-747 and partially resistant to JQ-EZ-05 in mammalian cells.
-
Depositing Labs
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 203586 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLX304
- Backbone size w/o insert (bp) 9377
- Total vector size (bp) 9963
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersBlasticidin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature30°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameEZH1
-
Alt nameEnhancer of zest 1 Polycomb repressive complex 2
-
Alt nameKMT6B
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2313
-
Mutationdeletion of aa 744-747 and partial resistance to JQ-EZ-05
-
GenBank ID2145
-
Entrez GeneEZH1 (a.k.a. KMT6B)
- Promoter CMV
-
Tag
/ Fusion Protein
- V5-tagged (C terminal on backbone)
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer CMV-F
- 3′ sequencing primer WPRE-R (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byBroad TRC (ccsbBroad304_00525)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
EZH1 was PCR amplified using a reverse primer that eliminated the PSET domain and sub-cloned using gateway cloning.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLX304-EZH1-dPSET was a gift from Abhishek Chakraborty & William Kaelin (Addgene plasmid # 203586 ; http://n2t.net/addgene:203586 ; RRID:Addgene_203586) -
For your References section:
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS, Pineda J, Song J, Wang YE, Carr SA, Root DE, Signoretti S, Bradner JE, Kaelin WG Jr. Sci Transl Med. 2017 Jul 12;9(398):eaal5272. doi: 10.1126/scitranslmed.aal5272. 10.1126/scitranslmed.aal5272 PubMed 28701475